The effects of MDR/RR-TB treatment on HIV disease: A systematic review of literature.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
06
2020
accepted:
19
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) and human immunodeficiency virus (HIV) co-infection are a deadly combination. While evidence on the effects of HIV co-infection on MDR/RR-TB treatment outcomes is well-documented, little published evidence describes the effects of MDR/RR-TB treatment on HIV disease. We conducted a review of literature published prior to June 2020. We searched Pubmed, CINAHL, and EMBASE using variations of the terms "multidrug-resistant tuberculosis," "HIV," and either "CD4" or "viral load." Two reviewers independently completed title and abstract screening, full-text screening, article evaluation, and data extraction. We also included five published articles evaluated as evidence by the World Health Organization (WHO) in preparation for the 2019 MDR/RR-TB treatment guideline update. A total of 459 references were returned, with 362 remaining after duplicate removal. Following article screening, six manuscripts were included. Articles reported CD4 count and/or viral load results for MDR/RR-TB and HIV co-infected patients during and/or after MDR/RR-TB treatment. The additional five references identified from the WHO guideline revision did not report HIV disease indicators after MDR/RR-TB initiation. There is a paucity of evidence on HIV disease indicators following MDR/RR-TB treatment. Researchers should report longitudinal HIV disease indicators in co-infected patients in publications.
Sections du résumé
BACKGROUND
Multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) and human immunodeficiency virus (HIV) co-infection are a deadly combination. While evidence on the effects of HIV co-infection on MDR/RR-TB treatment outcomes is well-documented, little published evidence describes the effects of MDR/RR-TB treatment on HIV disease.
METHODS
We conducted a review of literature published prior to June 2020. We searched Pubmed, CINAHL, and EMBASE using variations of the terms "multidrug-resistant tuberculosis," "HIV," and either "CD4" or "viral load." Two reviewers independently completed title and abstract screening, full-text screening, article evaluation, and data extraction. We also included five published articles evaluated as evidence by the World Health Organization (WHO) in preparation for the 2019 MDR/RR-TB treatment guideline update.
RESULTS
A total of 459 references were returned, with 362 remaining after duplicate removal. Following article screening, six manuscripts were included. Articles reported CD4 count and/or viral load results for MDR/RR-TB and HIV co-infected patients during and/or after MDR/RR-TB treatment. The additional five references identified from the WHO guideline revision did not report HIV disease indicators after MDR/RR-TB initiation.
CONCLUSION
There is a paucity of evidence on HIV disease indicators following MDR/RR-TB treatment. Researchers should report longitudinal HIV disease indicators in co-infected patients in publications.
Identifiants
pubmed: 33667271
doi: 10.1371/journal.pone.0248174
pii: PONE-D-20-19748
pmc: PMC7935310
doi:
Substances chimiques
Anti-HIV Agents
0
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0248174Subventions
Organisme : NIAID NIH HHS
ID : R01 AI104488
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet HIV. 2019 Mar;6(3):e201-e204
pubmed: 30846058
Lancet Infect Dis. 2019 Oct;19(10):1129-1137
pubmed: 31324519
Am J Trop Med Hyg. 2013 Dec;89(6):1233-1234
pubmed: 24306035
Clin Infect Dis. 2018 Apr 3;66(8):1246-1253
pubmed: 29293906
PLoS One. 2018 Mar 8;13(3):e0193491
pubmed: 29518098
BMC Infect Dis. 2019 Aug 16;19(1):723
pubmed: 31420021
Eur Respir J. 2018 Dec 20;52(6):
pubmed: 30361246
AIDS Behav. 2020 Oct;24(10):2754-2756
pubmed: 32356032
Int J Tuberc Lung Dis. 2012 Aug;16(8):998-1004
pubmed: 22668560
Lung India. 2018 Jan-Feb;35(1):4-8
pubmed: 29319026
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Eur Respir J. 2017 May 21;49(5):
pubmed: 28529205
PLoS One. 2012;7(10):e46943
pubmed: 23115633
Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7
pubmed: 23571542
J Infect. 2018 Jan;76(1):44-54
pubmed: 29061336
Int J Infect Dis. 2019 May;82:66-72
pubmed: 30844519
Emerg Infect Dis. 2019 May;25(5):936-943
pubmed: 31002070
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28182570
Int J Tuberc Lung Dis. 2018 Jul 1;22(7):766-772
pubmed: 29914602
Int J Tuberc Lung Dis. 2020 Jul 1;24(7):700-705
pubmed: 32718403
Am J Trop Med Hyg. 2013 Jul;89(1):174-7
pubmed: 23669229
PLoS One. 2014 Apr 10;9(4):e94393
pubmed: 24722139
PLoS One. 2012;7(11):e47370
pubmed: 23144818
Eur Respir J. 2016 Feb;47(2):564-74
pubmed: 26647431
Int J Tuberc Lung Dis. 2015 Aug;19(8):969-78
pubmed: 26162364
Clin Microbiol Infect. 2004 May;10(5):388-98
pubmed: 15113314